BR0013248A - Inibidores da adesão celular - Google Patents
Inibidores da adesão celularInfo
- Publication number
- BR0013248A BR0013248A BR0013248-9A BR0013248A BR0013248A BR 0013248 A BR0013248 A BR 0013248A BR 0013248 A BR0013248 A BR 0013248A BR 0013248 A BR0013248 A BR 0013248A
- Authority
- BR
- Brazil
- Prior art keywords
- cell adhesion
- adhesion inhibitors
- inhibitor
- disclosed
- vla
- Prior art date
Links
- 230000021164 cell adhesion Effects 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14884599P | 1999-08-13 | 1999-08-13 | |
PCT/US2000/022285 WO2001012186A1 (en) | 1999-08-13 | 2000-08-14 | Cell adhesion inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0013248A true BR0013248A (pt) | 2002-07-23 |
Family
ID=22527673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0013248-9A BR0013248A (pt) | 1999-08-13 | 2000-08-14 | Inibidores da adesão celular |
Country Status (32)
Country | Link |
---|---|
US (3) | US6630503B1 (pt) |
EP (2) | EP1265606B9 (pt) |
JP (1) | JP2003506491A (pt) |
KR (1) | KR100720907B1 (pt) |
CN (1) | CN1377268A (pt) |
AT (1) | ATE343383T1 (pt) |
AU (1) | AU780610B2 (pt) |
BG (1) | BG65755B1 (pt) |
BR (1) | BR0013248A (pt) |
CA (1) | CA2380817A1 (pt) |
CY (1) | CY1105912T1 (pt) |
CZ (1) | CZ2002518A3 (pt) |
DE (1) | DE60031577T2 (pt) |
DK (1) | DK1265606T3 (pt) |
EA (1) | EA005578B1 (pt) |
EE (1) | EE200200070A (pt) |
ES (1) | ES2270868T3 (pt) |
GE (2) | GEP20053477B (pt) |
HK (1) | HK1051500A1 (pt) |
HU (1) | HUP0202469A3 (pt) |
IL (2) | IL148014A0 (pt) |
IS (1) | IS6257A (pt) |
MX (1) | MXPA02001449A (pt) |
NO (1) | NO324044B1 (pt) |
NZ (1) | NZ517011A (pt) |
PL (1) | PL354063A1 (pt) |
PT (1) | PT1265606E (pt) |
RS (1) | RS50470B (pt) |
SK (1) | SK287075B6 (pt) |
UA (1) | UA75581C2 (pt) |
WO (1) | WO2001012186A1 (pt) |
ZA (1) | ZA200201158B (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
CA2380817A1 (en) * | 1999-08-13 | 2001-02-22 | Biogen, Inc. | Cell adhesion inhibitors |
DE10006453A1 (de) * | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
CN100471838C (zh) | 2000-12-28 | 2009-03-25 | 第一制药株式会社 | Vla-4抑制剂 |
JP2002201168A (ja) * | 2000-12-28 | 2002-07-16 | Kaken Pharmaceut Co Ltd | シクロヘキサン誘導体 |
JP2004526733A (ja) * | 2001-03-20 | 2004-09-02 | メルク エンド カムパニー インコーポレーテッド | 強力な細胞接着阻害剤としての置換n−アリールスルホニル−プロリン誘導体 |
US6663489B2 (en) | 2001-08-24 | 2003-12-16 | Igt | Gaming device having an award distributor and an award accumulator bonus game |
ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
TWI340134B (en) | 2003-07-24 | 2011-04-11 | Daiichi Seiyaku Co | Cyclohexanecarboxylic acids |
EP1706399A1 (en) * | 2004-01-23 | 2006-10-04 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
KR101273614B1 (ko) * | 2004-07-08 | 2013-06-12 | 엘란 파마슈티칼스, 인크. | 중합체 부분을 포함하는 다가 vla―4 길항제 |
US7196112B2 (en) * | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
BRPI0616574A2 (pt) | 2005-09-27 | 2009-11-24 | Shionogi & Co | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 |
HUE034863T2 (en) * | 2005-11-09 | 2018-03-28 | Onyx Therapeutics Inc | Compound for inhibiting enzyme |
BRPI0714799A2 (pt) * | 2006-08-02 | 2013-05-21 | Genzyme Corp | terapia de combinaÇço |
TW200817319A (en) | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
EP2124996A4 (en) | 2007-02-20 | 2010-03-24 | Merrimack Pharmaceuticals Inc | METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST |
WO2009126920A2 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
WO2015171610A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
CA2987289A1 (en) | 2015-06-11 | 2016-12-15 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
CA3019130A1 (en) * | 2016-04-01 | 2017-10-05 | The Regents Of The University Of California | Inhibitors of integrin alpha 5 beta 1 and methods of use |
CN109721605B (zh) * | 2017-10-31 | 2022-03-11 | 维眸生物科技(上海)有限公司 | 一种免疫细胞迁徙抑制剂 |
US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
JP7214882B2 (ja) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリン阻害剤としてのイミダゾピリジン誘導体 |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
CN112969687A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
KR20220047323A (ko) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1149971B (it) | 1979-06-11 | 1986-12-10 | Syntex Inc | Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante |
US4725583A (en) | 1985-01-23 | 1988-02-16 | Abbott Laboratories | Functionalized peptidylaminoalcohols |
US4826815A (en) | 1985-05-17 | 1989-05-02 | Abbott Laboratories | Renin inhibiting compounds |
GB2218102B (en) | 1988-04-08 | 1992-09-16 | Sandoz Ltd | Calcitonin peptide derivatives |
ATE75730T1 (de) | 1988-07-21 | 1992-05-15 | Pfizer | Verfahren zur herstellung substituierter guanylthioharnstoffe. |
US4908360A (en) | 1988-11-14 | 1990-03-13 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aminoalkyl-3-oxysubstituted-4-aryl-1,3,4,5-tetrahydro-2H-1,3-benzodiazepine-2-ones |
US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
DE69024230T2 (de) | 1989-12-22 | 1996-05-02 | Commw Scient Ind Res Org | An fette gebundene aminosäuren, peptide oder deren derivate |
CA2043741C (en) | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5260277A (en) | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
KR100291844B1 (ko) | 1991-06-11 | 2001-09-17 | 리차드 엘. 콘 | 세포간부착분자-3및그것의결합리간드 |
DE69226820T2 (de) | 1991-06-21 | 1999-05-12 | Merck & Co Inc | Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen |
US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5352667A (en) | 1991-11-22 | 1994-10-04 | Ofer Lider | Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them |
WO1993012809A1 (en) | 1991-12-24 | 1993-07-08 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
DE4212304A1 (de) | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
IL102646A (en) | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
EP0677060A1 (en) | 1993-01-08 | 1995-10-18 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
DE4309867A1 (de) | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
CA2159192C (en) | 1993-04-09 | 2006-07-25 | Keiichi Tanaka | Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases |
WO1995015973A1 (en) | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
US5770573A (en) | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
WO1997023480A1 (en) * | 1995-12-22 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
US6185453B1 (en) * | 1996-06-19 | 2001-02-06 | Dupont Pharmaceuticals Company | Iontophoretic delivery of integrin inhibitors |
AU3738597A (en) | 1996-07-25 | 1998-02-20 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
WO1998043962A1 (en) * | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
EP1017382B1 (en) | 1997-05-29 | 2006-03-01 | Merck & Co., Inc. (a New Jersey corp.) | Biarylalkanoic acids as cell adhesion inhibitors |
CA2291708A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
US6482849B1 (en) * | 1997-06-23 | 2002-11-19 | Tanabe Seiyaku Co., Ltd. | Inhibitors of α4β1 mediated cell adhesion |
CA2290749A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
CN1265669A (zh) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | 抑制由vla-4介导的白细胞粘着的化合物 |
NZ502580A (en) * | 1997-07-31 | 2001-06-29 | Elan Pharm Inc | 4-amino-phenylalanine compounds which inhibit leukocyte adhesion mediated by VLA-4 |
NZ502582A (en) * | 1997-07-31 | 2002-07-26 | American Home Prod | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CA2291475A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
CN1265672A (zh) * | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | 能抑制由vla-4介导的白细胞粘连的磺酰化二肽化合物 |
BR9811988A (pt) * | 1997-08-22 | 2000-09-05 | Hoffmann La Roche | Derivados de n-alcanoilfenilalanina |
ATE267801T1 (de) | 1997-08-22 | 2004-06-15 | Hoffmann La Roche | N-alkanoylphenylalaninderivate |
DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
AR013693A1 (es) * | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria |
CN1327443A (zh) * | 1997-10-31 | 2001-12-19 | 艾文蒂斯药品有限公司 | 取代的酰苯胺化合物 |
AU1411499A (en) | 1997-11-20 | 1999-06-15 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
WO1999026922A1 (en) | 1997-11-21 | 1999-06-03 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
ATE267168T1 (de) | 1997-11-24 | 2004-06-15 | Merck & Co Inc | Beta-alanin-derivate als zell-adhäsions- inhibitoren |
WO1999026945A1 (en) * | 1997-11-26 | 1999-06-03 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS |
US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6329372B1 (en) * | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
AU3260399A (en) * | 1998-02-26 | 1999-09-15 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
DE69935133T2 (de) * | 1998-03-27 | 2007-11-22 | Genentech, Inc., South San Francisco | Antagonisten zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten |
SI1082302T1 (en) | 1998-05-28 | 2004-06-30 | Biogen, Inc. | A vla-4 inhibitor: omepupa-v |
TW591026B (en) * | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
US6303625B1 (en) * | 1998-07-27 | 2001-10-16 | Ortho-Mcneil Pharmaceutical, Inc. | Triazolopyridines for the treatment of thrombosis disorders |
US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
ATE261932T1 (de) * | 1998-12-22 | 2004-04-15 | Tanabe Seiyaku Co | Inhibitoren der alpha-4 beta-1 vermittelten zelladhäsion |
EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
ATE264835T1 (de) * | 1999-02-18 | 2004-05-15 | Hoffmann La Roche | Phenylalaninolderivate |
CA2380817A1 (en) * | 1999-08-13 | 2001-02-22 | Biogen, Inc. | Cell adhesion inhibitors |
JP2001089448A (ja) * | 1999-09-24 | 2001-04-03 | Yamanouchi Pharmaceut Co Ltd | アミド誘導体 |
US7196112B2 (en) * | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
-
2000
- 2000-08-14 CA CA002380817A patent/CA2380817A1/en not_active Abandoned
- 2000-08-14 CZ CZ2002518A patent/CZ2002518A3/cs unknown
- 2000-08-14 EE EEP200200070A patent/EE200200070A/xx unknown
- 2000-08-14 PT PT00959232T patent/PT1265606E/pt unknown
- 2000-08-14 GE GE4744A patent/GEP20053477B/en unknown
- 2000-08-14 WO PCT/US2000/022285 patent/WO2001012186A1/en active IP Right Grant
- 2000-08-14 JP JP2001516532A patent/JP2003506491A/ja active Pending
- 2000-08-14 NZ NZ517011A patent/NZ517011A/en unknown
- 2000-08-14 IL IL14801400A patent/IL148014A0/xx unknown
- 2000-08-14 AT AT00959232T patent/ATE343383T1/de not_active IP Right Cessation
- 2000-08-14 KR KR1020027001850A patent/KR100720907B1/ko not_active IP Right Cessation
- 2000-08-14 GE GE5468A patent/GEP20063956B/en unknown
- 2000-08-14 UA UA2002032010A patent/UA75581C2/uk unknown
- 2000-08-14 HU HU0202469A patent/HUP0202469A3/hu unknown
- 2000-08-14 MX MXPA02001449A patent/MXPA02001449A/es active IP Right Grant
- 2000-08-14 EA EA200200253A patent/EA005578B1/ru not_active IP Right Cessation
- 2000-08-14 US US09/638,652 patent/US6630503B1/en not_active Expired - Fee Related
- 2000-08-14 SK SK215-2002A patent/SK287075B6/sk not_active IP Right Cessation
- 2000-08-14 RS YUP-98/02A patent/RS50470B/sr unknown
- 2000-08-14 ES ES00959232T patent/ES2270868T3/es not_active Expired - Lifetime
- 2000-08-14 CN CN00813728A patent/CN1377268A/zh active Pending
- 2000-08-14 EP EP00959232A patent/EP1265606B9/en not_active Expired - Lifetime
- 2000-08-14 AU AU70586/00A patent/AU780610B2/en not_active Ceased
- 2000-08-14 DK DK00959232T patent/DK1265606T3/da active
- 2000-08-14 DE DE60031577T patent/DE60031577T2/de not_active Expired - Lifetime
- 2000-08-14 PL PL00354063A patent/PL354063A1/xx not_active Application Discontinuation
- 2000-08-14 BR BR0013248-9A patent/BR0013248A/pt not_active Application Discontinuation
- 2000-08-14 EP EP06021333A patent/EP1741428A3/en not_active Withdrawn
-
2002
- 2002-01-31 IS IS6257A patent/IS6257A/is unknown
- 2002-02-05 IL IL148014A patent/IL148014A/en not_active IP Right Cessation
- 2002-02-11 ZA ZA200201158A patent/ZA200201158B/en unknown
- 2002-02-13 NO NO20020725A patent/NO324044B1/no not_active IP Right Cessation
- 2002-03-11 BG BG106510A patent/BG65755B1/bg unknown
-
2003
- 2003-05-27 HK HK03103786A patent/HK1051500A1/xx not_active IP Right Cessation
- 2003-10-03 US US10/677,756 patent/US7034043B2/en not_active Expired - Fee Related
-
2006
- 2006-02-27 US US11/362,043 patent/US20060166961A1/en not_active Abandoned
-
2007
- 2007-01-09 CY CY20071100027T patent/CY1105912T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0013248A (pt) | Inibidores da adesão celular | |
ATE297203T1 (de) | Antithrombotische mitteln | |
ATE306261T1 (de) | Antithrombosemittel | |
BR0314113A (pt) | Derivados de amino propanol | |
BR0206738A (pt) | Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase | |
BR0206433A (pt) | Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto | |
BR0317268A (pt) | Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos | |
BR0308081A (pt) | Inibidores de histona desacetilase | |
DE69919212D1 (de) | Aromatische amiden | |
TR199902606T2 (xx) | Farnesil transferaz� engelleyici kinazolinonlar. | |
BR0010555A (pt) | Inibidores de neuraminidases | |
BR0007589A (pt) | Inibidores da proliferação de células | |
BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
BR0209948A (pt) | Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos | |
BR9911013A (pt) | Derivados de pirazol como inibidores da p-38 map quinase | |
BR0014116A (pt) | Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
BR0307575A (pt) | Derivados de sulfonila como inibidores de histona desacetilase | |
BR0306150A (pt) | Composto, uso de um composto, e, composição farmacêutica | |
BR0315143A (pt) | Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto | |
ATE292634T1 (de) | Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion | |
ATE495187T1 (de) | Dalda-analoge und ihre verwendung | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BRPI0409465A (pt) | derivados de carboxamida como agentes antidiabéticos | |
BR0004535A (pt) | Compostos, e, uso dos mesmos. | |
BR0314363A (pt) | Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN IDEC MA, INC. (US) Free format text: ALTERADO DE: BIOGEN, INC. |
|
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN IDEC MA INC. (US) Free format text: ALTERADO DE: BIOGEN IDEC MA, INC. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 31/40, A61K 31/4025, A61K 31/445, C07D 401/06, C07D 401/10, C07D 401/12 Ipc: C07D 207/48 (2010.01), A61K 31/40 (2010.01) |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |